REDWOOD CITY, Calif., March 21, 2011 /PRNewswire/ -- MyoScience, Inc. today announced that aesthetic industry veteran Clint Carnell has been appointed President and CEO of the Company, effective April 1, 2011. Mr. Carnell was previously COO of Solta Medical, Inc. a leading publicly traded company in Aesthetics. Prior to Solta Medical, Mr. Carnell served as Vice President of Sales for the Surgical Division of Bausch & Lomb.
"I am thrilled to be joining MyoScience at this stage of company development, the Team has done an excellent job of positioning the company for commercial success. As a veteran of both Ophthalmic and Aesthetic medical device markets, I've had the opportunity to view many emerging technologies and believe that the MyoScience cold-based technology has the opportunity to be a real game changer. I look forward to working with the MyoScience Team and Board," said Clint Carnell.
"Clint was a natural choice for the position. He has relationships with key influencers in aesthetics, a demonstrated track record of scaling companies for success and a reputation for leadership that will be critical as we position the Company for commercial launch," said Rich Ferrari, MyoScience Chairman and DeNovo Ventures Managing Director.
About MyoScience, Inc.
MyoScience, Inc., founded in 2005 with headquarters in Redwood City, California, is a privately held, pre-commercial stage company.
MyoScience is developing an innovative medical device and minimally invasive procedure to deliver a precisely controlled subcutaneous cooling effect to relax facial muscles that cause dynamic facial wrinkles to form. The patented CRYNEUROMODULATION™ procedure would be expected to offer specialty aesthetic physicians a medically proven procedure for the very large group of patients who prefer a new neurotoxin-free alternative to BOTOX® Cosmetic, Dysport®, or other brands of neurotoxin compounds.
The MyoScience technology has been cleared by the U.S. FDA for general surgical use and for the treatment of peripheral nerves for relieving pain. The MyoScience CRYONEUROMODULATION™ technology is not cleared for use in the U.S. for aesthetic applications. It is currently in clinical trials for reducing dynamic facial wrinkles (such as frown lines between the brows, forehead lines, and crow's feet) in the upper face.
MyoScience is backed by an experienced group of medical technology venture capital investors, including: De Novo Ventures, Accuitive Medical Ventures, Nexus Medical Partners, Saratoga Ventures, and Medicis Capital GmbH.
CRYONEUROMODULATION™ is a trademark of MyoScience, Inc.
BOTOX® is a registered trademarks of Allergan, Inc.
Dysport® is a registered trademark of Ipsen Biopharm Limited
President and CEO
SOURCE MyoScience, Inc.